Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Cancer and its treatment can cause problems with attention, memory, and learning. These cognitive difficulties may affect your daily activities and worsen your quality of life.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description. 
Researchers are assessing the safety of the drug VT3989 in people with mesothelioma. The people in this study have mesothelioma with a mutation (change or variant) in the NF2 gene.
Researchers want to find the best dose of AZD0305 to use in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. AZD0305 is given intravenously (by vein).
Researchers are assessing a personalized cancer vaccine called V940 plus pembrolizumab immunotherapy to prevent lung cancer recurrence. The people in this study had surgery to remove non-small cell lung cancer (NSCLC), followed by chemotherapy.
Osimertinib is a standard treatment for metastatic non-small cell lung cancer (NSCLC) that has a change (mutation) in the EGFR gene. Researchers think that adding chemotherapy to osimertinib could make treatment more effective.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
In this study, researchers want to see if giving the drug 177Lu-PSMA-617 followed by stereotactic body radiation therapy (SBRT) is safe for men with prostate cancer that is responsive to hormonal therapy ("hormone-sensitive prostate cancer") and has spread to one to three sites. 177Lu-PSMA-617 targets prostate cancer cells and delivers radiation directly into the tumor to destroy cancer cells.
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
